A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting innovative actions, it encourages more companies to seize opportunities for change.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Publications
  • Ensuring sustained incentives for pharma to d...
Publication - published on 06 Jun 2016

Ensuring sustained incentives for pharma to develop medicine for the poor

A commentary by Clarke B. Cole and Jayasree K. Iyer, explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of R&D models in incentivising these contributions.

This article details how pharma companies engage with the Product Development Partnership (PDP) model and other models that are based on the combined principles of open collaboration and access to medicine.



Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.